Recent Advances in the Detection and Pathophysiology of Steatotic, Alcoholic and Drug-Induced Liver Diseases
A special issue of Livers (ISSN 2673-4389).
Deadline for manuscript submissions: 10 June 2025 | Viewed by 1145
Special Issue Editors
Interests: hepatology; liver tissue engineering; drug-induced liver injury; liver disease; synthetic biology; Alzheimer's disease
2. Research Center for Toxicogenomics and Human Health (ToxOmics), Universidade NOVA de Lisboa, 1099-085 Lisboa, Portugal
Interests: pharmaco-/toxicokinetics; pharmaco-/toxicogenomics; drug metabolism; cytochrome P450; adverse drug reactions (ADRs); drug-induced liver injury (DILI); cancer drug resistance; metabolic liver disease
Special Issues, Collections and Topics in MDPI journals
Interests: liver disease modelling; early liver pathogenesis; MASLD/MASH
Special Issue Information
Dear Colleagues,
Chronic liver diseases (CLDs) have emerged as a leading cause of hepatic-related morbidity and mortality worldwide. Amongst these, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), alcoholic liver disease (ALD), and drug-induced liver injury (DILI) result from one or a combination of genetic, environmental, and lifestyle-associated factors, such as diet-induced obesity, metabolic dysfunction, alcohol misuse, and drug toxicity. The late detection of CLDs, owing to their insidious nature and heterogeneous pathophysiology, significantly limits the use of therapeutic options that aim to halt or reverse disease progression. A promising avenue for improved patient prognosis lies in the identification of cell-type and disease-specific biomarkers, especially those that can be detected at the early stages of disease. We invite submissions that highlight the latest advancements in pathophysiological and inflammatory mechanisms underlying CLDs (excluding those with viral or autoimmune origins). Contributions that examine novel pathogenic pathways, cellular interactions, biomarker discovery and characterisation, mixed aetiologies (e.g., MASLD-DILI), precision medicine, and the influence of lifestyle and environmental factors on CLD progression are particularly encouraged. This Special Issue aims to compile recent breakthroughs in research that will enhance the early diagnosis and targeted treatment of CLDs, paving the way for improved patient outcomes.
Dr. Leonard Nelson
Dr. Michel Kranendonk
Dr. Anabel Martinez Lyons
Dr. Francisco Esteves
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Livers is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acetaminophen-induced hepatotoxicity
- alcoholic liver disease (ALD)
- biomarkers and molecular targeting for CLDs
- chronic liver disease (CLD)
- drug-induced liver injury (DILI)
- extracellular microenvironment and cell-cell communication in CLDs
- genetic variants influencing MASLD-MASH
- hepatic inflammation
- in vitro and in vivo CLD modelling
- lipotoxicity
- metabolic dysfunction-associated steatohepatitis (MASH)
- metabolic dysfunction-associated steatotic liver disease (MASLD)
- multiomics and systems biology
- new tools and technologies in the study of CLDs
- novel therapeutic strategies for CLDs and precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
